Abstract
Background: Sleep is increasingly recognized as essential to human health, yet the adverse health consequences of acute sleep deprivation are unknown. Using actigraphic, genomic, and health data from the All of Us (AoU) Research Program, we characterized the detrimental health consequences of acute sleep deprivation in the American public. Methods: LOESS smoothing was performed on sleep estimates from Fitbit users (N = 14,681) between June 1, 2016 and July 1, 2022. Dates when population minutes slept were less than the 90% confidence interval of the LOESS regression were named acute sleep deprivation events (ASDEs). Phenome-wide disease incidence among the AoU population (N = 287,012) in the 10 days post-ASDE was compared to a preceding reference period by McNemar test. Circadian rhythm and sleep duration-associated SNPs were screened to identify genotypes associated with shorter ASDE sleep duration. Influences of sleep and circadian genotype on post-ASDE influenza risk were modeled using binomial family generalized estimating equations. Findings: We identified 32 ASDEs spanning political and non-political events. A phenome-wide screen found increased risk of influenza (OR = 1.54 [1.40, 1.70], P-value = 1.00 x 10-18) following ASDEs. 56 SNPs were associated with decreased sleep duration on ASDEs. Higher quantiles of ASDE-related SNP genotype burden were associated with less ASDE sleep duration and a greater risk of influenza-associated healthcare visits. Interpretation: National political and non-political events are associated with acute sleep deprivation and greater influenza risk which is amplified by sleep genotypes. These findings should inform public health vigilance surrounding major national events.
Competing Interest Statement
S.Y.C. has served as a consultant for Merck, Janssen, and United Therapeutics; S.Y.C. is a director, officer, and shareholder in Synhale Therapeutics; S.Y.C. holds research grants from United Therapeutics, Bayer, and WoodNext Foundation. S.Y.C. has filed patent applications regarding the targeting of metabolism in pulmonary hypertension. Other authors: none.
Funding Statement
This work was supported by the WoodNext Foundation (S.Y.C. and C.A.M.); NIH grants T32 HL129964 (N.J.K. and R.C.), R01 HL124021 (S.Y.C.), R01 HL122596 (S.Y.C.); R01 HL151228 (S.Y.C.); AHA grants 24SFRNCCN1276089 and 24SFRNPCN1280228 (S.Y.C.); and the McKamish Family Foundation, the Hemophilia Center of Western Pennsylvania, and the Institute for Transfusion Medicine (N.J.K. and R.C.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In accordance with the All of Us Research Program, this study was exempt from human subject approval and only deidentified data were analyzed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available to authorized users of the All of Us Research Program Controlled Tier Dataset 7 on the Researcher Workbench at https://www.researchallofus.org/.
